scholarly journals Investigation of regenerative and tiss ue-specific activity of tot al RNA of bone marrow cells

2018 ◽  
Vol 20 (3) ◽  
pp. 64-69
Author(s):  
Z. Z. Gonikova ◽  
A. O. Nikolskaya ◽  
L. A. Kirsanova ◽  
M. Yu. Shagidulin ◽  
N. A. Onishchenko ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Specific Activity ◽  
Cell Activity ◽  
Total Rna ◽  
Liver And Kidney ◽  
Group 3 ◽  
Group 2 ◽  
Group 1 ◽  
Marrow Cells

Aim. To establish the ability of the total RNA extracted from the body’s bone marrow cells (BMCs), in which liver tissue was damaged, to serve as a carrier of targeted regenerative signals to this organ.Materials and methods. By method of adoptive transfer in rats (n = 37) the  mitotic and proliferative activity of liver and kidney cells were studied in intact  recipients after intraperitoneal injection: the mononuclear BMCs – 2,5×106;  5,0×106; 3,5×107 cells – group 1 and the total RNA of the same BMCs  (30μg/100g of weight) – group 2 from donors in 12 hours after 70–75% of  hepatectomy; in group 3 (control), a saline solution was injected. RNA from  BMCs was extracted by the method developed by the «Evrogen» firm (Russia) with the reagent Extract RNA.Results. In group 2 in 48 and 72 h. there was the increasing of mitotic and  proliferative cell activity in the liver, but not in the kidneys (control of the  specificity of regenerative signals); in group 1 there was no transfer of  regenerative signals to these organs.Conclusion. The authors believe that the total RNA from BMCs, activated by hepatectomy, accumulates targeted (hepatospecific) regeneration signals, but  they are perceived only when RNA has been obtained by the damaged tissue.

scholarly journals Coadministration of bone marrow cells and an inhibitor of apoptosis (Z-VAD) promotes bone marrow cell survival and neurological functional recovery after focal cerebral ischemia in adult rat

Stroke ◽  
2001 ◽  
Vol 32 (suppl_1) ◽  
pp. 379-380
Author(s):  
Yi Li ◽  
Jieli Chen ◽  
Michael Chopp
Keyword(s):  
Bone Marrow ◽  
Cerebral Ischemia ◽  
Bone Marrow Cells ◽  
Inhibitor Of Apoptosis ◽  
Apoptotic Cells ◽  
Group 3 ◽  
Group 2 ◽  
Adhesive Removal ◽  
Group 1 ◽  
Marrow Cells

P222 Most bone marrow cells (BMCs) transplanted into the ischemic brain of adult rodents die shortly after they are grafted, similar to the 90%-95% of the fetal cells that die after transplantation into Parkinson s patients. We tested whether coadministration of BMCs and Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD), an inhibitor of apoptosis, into the ischemic boundary zone of the striatum and the cortex in rat brain promotes BMC survival. Adult Wistar rats were subjected to transient (2 h) middle cerebral artery occlusion (MCAo). At 1 d after ischemia, saline (n=9, Group 1); BMCs (1x10 6 in 10 :l, n=8, Group 2); or BMCs with Z-VAD (50 nM/ml, n=4, Group 3) were injected into brain. BMCs were harvested from donor adult rats injected with bromodeoxyuridine (BrdU, as a tracer). Rats were subjected to rotarod-motor and adhesive-removal somatosensory functional tests before MCAo and at 1 and 7 d after MCAo. Rats in Group 3 exhibited significant improvement (10.3±2.6 seconds, p<0.05) on the adhesive-removal test at 7 d, compared with those in Group 1 (29.3±9.4 seconds) and Group 2 (21.3±5.5 seconds), respectively. Immunohistochemistry staining was employed to identify BrdU-BMCs, and TUNEL staining was used to identify in situ DNA fragmentation of apoptotic cells. Even though the infarct volume in Group 3 (29.9±9.2%) did not change significantly, compared with Group 1 (34.3±4.0%) and Group 2 (26.6±3.8%); the number of BrdU-BMCs (88,200±7,400, ∼8.8% of 10 6 transplanted cells) increased significantly (p<0.05) in rats in Group 3, compared with that in Group 2 (31,700±9,100, ∼3.2% of 10 6 cells) at 7 d. In the grafting areas, apoptotic cells were less clustered (<90 vs.>240 per region) and apoptotic cells were significantly decreased (12.3±1.7/mm 2 vs. 25.9±2.1/mm 2 , ∼47%, p<0.05). Our data suggest that intracerebral coadministration of bone marrow cells and inhibitors of apoptosis enhance cellular survival of bone marrow cells and improves neurological functional recovery after cerebral ischemia.

Serum Transferrin Receptor Value as a Universal Indicator of Erythropoietic Activity.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3682-3682
Author(s):  
Young Soo Lee ◽  
Chul Soo Kim ◽  
Jong Weon Choi
Keyword(s):  
Bone Marrow ◽  
Transferrin Receptor ◽  
Bone Marrow Cells ◽  
Reticulocyte Count ◽  
Serum Transferrin Receptor ◽  
Group 4 ◽  
Universal Indicator ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Abstract The serum transferrin receptor (sTfR) is thought a sensitive and quantitative parameter of tissue iron deficiency as well as an indicator of erythropoietic activity. This study was aimed at the verification of a hypothesis that sTfR is a general indicator of erythropoiesis regardless whatever the cause is. A total of 173 patients in heterogeneous diseases who underwent bone marrow study as a workup for anemia were measured for sTfR, reticulocyte maturity index (RMI), erythroid element proportion of bone marrow cells, and other hematologic parameters (hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, red cell distribution width, absolute reticulocyte count). By immunoenzymometric method sTfR was measured using IDeATMcTfR kids (Orion Diagnostica, Orion, Finland). Reticulocyte count and proportion was measured manually by one expert examiner after standard blood smear and stain. Reticulocyte subpopulation was automatically analyzed by flow cytometry using R-3000 TM (Sysmex, TOA, Japan). RMI was calculated from the equation of (medium fluorescent reticulocyte fraction + high fluorescent reticulocyte fraction) X 100 / low fluorescent reticulocyte fraction. Correlation analysis was done among the variables including sTfR, RMI, erythroid element proportion of bone marrow cells, and other hematologic parameters using SAS 6.12 soft ware. The analysis was carried out for the whole 173 patients to see the general trends and repeated for 4 groups of disease category, arbitrarily divided to group 1 (n=33, iron deficiency or or disease with no predisposition to anemia of chronic disease), group 2 (n=53, hematologic malignancies), group 3 (n=44, solid tumors), and group 4 (n=43, chronic or infectious disease) to see if the trends may be affected by specific diseases. The results showed a solid correlation of sTfR with RMI as well as erythroid precursors in bone marrow, not only in the whole patient population (e.g. sTfR vs RMI, R=0.587, p=0.0001) but also in individual groups (e.g. sTfR vs RMI, R=0.48, p=0.005 in group 1, R=0.69, p=0.0001 in group 2, R=0.58, p=0.0001 in group 3, R=0.81, p=0.0001 in group 4). These findings indicated the significance of sTfR is valid under any clinical setting as a universal indicator of hematopoietic activity. The sTfR can be used as a useful parameter for monitoring of erythropoiesis in a variety disease.

Abelson virus potentiates long-term growth of mature B lymphocytes

1986 ◽  
Vol 6 (1) ◽  
pp. 183-194
Author(s):  
L A Serunian ◽  
N Rosenberg
Keyword(s):  
Bone Marrow ◽  
B Cells ◽  
B Cell ◽  
Cell Lines ◽  
Bone Marrow Cells ◽  
Mouse Bone Marrow ◽  
Phenotypic Characteristics ◽  
Group 2 ◽  
Group 1 ◽  
Marrow Cells

Abelson murine leukemia virus (A-MuLV) infection of mouse bone marrow cells usually leads to transformation of pre-B cells. However, when the environment is modified by the continuous presence of lipopolysaccharide (LPS), two novel types of membrane immunoglobulin (mIg)-positive B cell lines are generated. Because the cells which give rise to these cell lines copurify with mIg-positive bone marrow cells, the cell lines arise as a result of A-MuLV interaction with a new type of in vitro target cell. The cell lines generated fall into two groups which differ in several phenotypic characteristics. Group 1 cells are more differentiated than the typical pre-B cell transformant in that they synthesize mIgM and appear to resemble virgin B cells. The group 1 cells do not secrete immunoglobulin and are independent of LPS for growth. In addition, these cell lines synthesize the Abelson P160 protein, contain integrated abl proviral DNA, and are highly tumorigenic in syngeneic animals. The group 2 cell lines differ markedly from both the group 1 cells and from typical, pre-B cell A-MuLV transformants. These cells are mIgG positive and secrete large amounts of immunoglobulin into the culture medium. The cell lines are comprised of both adherent and nonadherent cells and do not synthesize P160 or contain integrated v-abl sequences. The group 2 cells are nontumorigenic in syngeneic animals and require LPS for growth and viability. Both types of cells have remained in culture for over 2 years with no changes in their phenotypic characteristics. This A-MuLV infection system and the novel mIg-positive cell lines may serve as useful models for studying biochemical and molecular properties of mature B cells.

scholarly journals Abelson virus potentiates long-term growth of mature B lymphocytes.

1986 ◽  
Vol 6 (1) ◽  
pp. 183-194 ◽  
Author(s):  
L A Serunian ◽  
N Rosenberg
Keyword(s):  
Bone Marrow ◽  
B Cells ◽  
B Cell ◽  
Cell Lines ◽  
Bone Marrow Cells ◽  
Mouse Bone Marrow ◽  
Phenotypic Characteristics ◽  
Group 2 ◽  
Group 1 ◽  
Marrow Cells

Abelson murine leukemia virus (A-MuLV) infection of mouse bone marrow cells usually leads to transformation of pre-B cells. However, when the environment is modified by the continuous presence of lipopolysaccharide (LPS), two novel types of membrane immunoglobulin (mIg)-positive B cell lines are generated. Because the cells which give rise to these cell lines copurify with mIg-positive bone marrow cells, the cell lines arise as a result of A-MuLV interaction with a new type of in vitro target cell. The cell lines generated fall into two groups which differ in several phenotypic characteristics. Group 1 cells are more differentiated than the typical pre-B cell transformant in that they synthesize mIgM and appear to resemble virgin B cells. The group 1 cells do not secrete immunoglobulin and are independent of LPS for growth. In addition, these cell lines synthesize the Abelson P160 protein, contain integrated abl proviral DNA, and are highly tumorigenic in syngeneic animals. The group 2 cell lines differ markedly from both the group 1 cells and from typical, pre-B cell A-MuLV transformants. These cells are mIgG positive and secrete large amounts of immunoglobulin into the culture medium. The cell lines are comprised of both adherent and nonadherent cells and do not synthesize P160 or contain integrated v-abl sequences. The group 2 cells are nontumorigenic in syngeneic animals and require LPS for growth and viability. Both types of cells have remained in culture for over 2 years with no changes in their phenotypic characteristics. This A-MuLV infection system and the novel mIg-positive cell lines may serve as useful models for studying biochemical and molecular properties of mature B cells.

scholarly journals The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts

2021 ◽  
Vol 69 (1) ◽  
Author(s):  
Arkadiusz Jundziłł ◽  
Aleksandra Klimczak ◽  
Erhan Sonmez ◽  
Grzegorz Brzezicki ◽  
Maria Siemionow
Keyword(s):  
Bone Marrow ◽  
T Cells ◽  
Peripheral Blood ◽  
Bone Marrow Cells ◽  
Allogeneic Bone ◽  
Group 4 ◽  
Donor Bone Marrow ◽  
Group 3 ◽  
Group 2 ◽  
Marrow Cells

AbstractUsing the vascularized skin allograft (VSA) model, we compared the tolerogenic effects of different allogeneic bone marrow transplantation (BMT) delivery routes into immunoprivileged compartments under a 7-day protocol immunosuppressive therapy. Twenty-eight fully MHC mismatched VSA transplants were performed between ACI (RT1a) donors and Lewis (RT11) recipients in four groups of seven animals each, under a 7-day protocol of alfa/beta TCRmAb/CsA (alpha/beta-TCR monoclonal antibodies/Cyclosporine A therapy). Donor bone marrow cells (BMC) (100 × 106 cells) were injected into three different immunoprivileged compartments: Group 1: Control, without cellular supportive therapy, Group 2: Intracapsular BMT, Group 3: Intragonadal BMT, Group 4: Intrathecal BMT. In Group 2, BMC were transplanted under the kidney capsule. In Group 3, BMC were transplanted into the right testis between tunica albuginea and seminiferous tubules, and in Group 4, cells were injected intrathecally. The assessment included: skin evaluation for signs and grade of rejection and immunohistochemistry for donor cells engraftment into host lymphoid compartments. Donor-specific chimerism for MHC class I (RT1a) antigens and the presence of CD4+/CD25+ T cells were assessed in the peripheral blood of recipients. The most extended allograft survival, 50–78 days, was observed in Group 4 after intrathecal BMT. The T cells CD4+/CD25+ in the peripheral blood were higher after intrathecal BMC injection than other experimental groups at each post-transplant time point. Transplantation of BMC into immunoprivileged compartments delayed rejection of fully mismatched VSA and induction of robust, donor-specific chimerism.

scholarly journals Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts

2021 ◽  
Vol 69 (1) ◽  
Author(s):  
Joanna Cwykiel ◽  
Arkadiusz Jundzill ◽  
Aleksandra Klimczak ◽  
Maria Madajka-Niemeyer ◽  
Maria Siemionow
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Fluorescent Microscopy ◽  
Study Endpoint ◽  
Solid Organ ◽  
Post Transplant ◽  
Group 4 ◽  
Cell Based Therapy ◽  
Group 3 ◽  
Group 1

AbstractThis study evaluated the efficacy of donor recipient chimeric cell (DRCC) therapy created by fusion of donor and recipient derived bone marrow cells (BMC) in chimerism and tolerance induction in a rat vascularized composite allograft (VCA) model. Twenty-four VCA (groin flaps) from MHC-mismatched ACI (RT1a) donors were transplanted to Lewis (RT1l) recipients. Rats were randomly divided into (n = 6/group): Group 1—untreated controls, Groups 2—7-day immunosuppression controls, Group 3—DRCC, and Group 4—DRCC with 7-day anti-αβTCR monoclonal antibody and cyclosporine A protocol. DRCC created by polyethylene glycol-mediated fusion of ACI and Lewis BMC were cultured and transplanted (2–4 × 106) to VCA recipients via intraosseous delivery route. Flow cytometry assessed peripheral blood chimerism while fluorescent microscopy and PCR tested the presence of DRCC in the recipient’s blood, bone marrow (BM), and lymphoid organs at the study endpoint (VCA rejection). No complications were observed after DRCC intraosseous delivery. Group 4 presented the longest average VCA survival (79.3 ± 30.9 days) followed by Group 2 (53.3 ± 13.6 days), Group 3 (18 ± 7.5 days), and Group 1 (8.5 ± 1 days). The highest chimerism level was detected in Group 4 (57.9 ± 6.2%) at day 7 post-transplant. The chimerism declined at day 21 post-transplant and remained at 10% level during the entire follow-up period. Single dose of DRCC therapy induced long-term multilineage chimerism and extended VCA survival. DRCC introduces a novel concept of customized donor-recipient cell-based therapy supporting solid organ and VCA transplants.

Mobilization of Stem Cells from the Bone Marrow Is Required for Neovascularization of Ischemic Limbs in Mice.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4233-4233
Author(s):  
Jeong-A Kim ◽  
Chang -Hoon Lee ◽  
Jin-A. Yoon ◽  
Woo-Sung Min ◽  
Chun-Choo Kim
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Hind Limb ◽  
Limb Ischemia ◽  
Hind Limb Ischemia ◽  
Ischemic Limb ◽  
Group 3 ◽  
Group 2 ◽  
Surgically Induced ◽  
Group 1

Abstract We examined whether the injection of bone marrow mononuclear cells (BM-MNCs) or mesenchymal stem cells (MSCs) might augment angiogenesis and collateral vessel formation in a mouse model of hind limb ischemia. C57BL/6 BM-MNCs were isolated by centrifugation through a Histopaque density gradient and MSCs were obtained from C57BL/6 bone marrow and cultured in low-glucose DMEM media. Unilateral hind limb ischemia was surgically induced in C57BL/6 mice (control; n=4), and autologous BM-MNCs (Group 1; n=4, 1.8±0.2 x107/animal) or MSCs (Group 2; n=4, 1.0±0.14 x106/animal) or BM-MNCs and MSCs (Group 3; n=4, 2.3±0.1 x107 and 1.1±0.21 x106/animal) were transplanted into the ischemic tissue. Six weeks after transplantation, the group 1, group 2 and group 3 had a higher capillary/muscle ratio (0.82±0.12 vs 0.85±0.08 vs 0.97 ±0.03) than control (0.46±0.12, p&lt;0.05) (Fig. 1). This result suggested that direct local transplantation of autologous BM-MNCs or MSCs seems to be a useful strategy for therapeutic neovascularization in ischemic tissues. Next, we evaluated whether bone marrow derived stem cells were participated in the process of local injected stem cells forming new vessels. In general, mobilizing stem cells from bone marrow to local site, MMP-9 has been known as an important molecule. So we used the MMP-9 deficient KO mice and wild type, 129SvEv mice were used in the experiments. Autologous BM-MNCs and MSCs were transplanted into the ischemic limb in MMP-9 (−/−) (n=4) after unilateral hind limb ischemia was surgically induced and then the same experiments was done in MMP-9 (+/+) mice (n=4). The number of the injected BM-MNCs and MSCs was 2.2±0.05 x107 and 0.87±0.17 x106/animal in MMP-9 (−/−). And the number of the injected BM-MNCs and MSCs was 2.1±0.17 x107 and 0.98±0.09 x106/animal in MMP-9 (+/+). No difference was seen in the BM-MNCs and MSCs were injected or not (0.52±0.07 vs 0.49±0.03,) in MMP-9 (−/−). But, in the case that BM-MNCs and MSCs were injected, the higher capillary/muscle ratio was seen in MMP-9 (+/+) compared to control (0.86 ±0.09 vs 0.49±0.03, P&lt;0.05) (Fig 2). This data indicated that the mobilization of bone marrow derived stem cells would have an important role in the neovasculrization although the stem cells were injected directly into the muscle of ischemic limb. Figure Figure Figure Figure

scholarly journals Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.

1989 ◽  
Vol 9 (6) ◽  
pp. 2665-2671 ◽  
Author(s):  
G F Tidmarsh ◽  
S Heimfeld ◽  
C A Whitlock ◽  
I L Weissman ◽  
C E Müller-Sieburg
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Leukemia Virus ◽  
Cell Activity ◽  
Mouse Bone Marrow ◽  
Hematopoietic Stem ◽  
Low Levels ◽  
B Lineage ◽  
Marrow Cells

A novel stage in early B-lymphocyte differentiation has been identified in normal mouse bone marrow cells. Earlier work had demonstrated that bone marrow cells characterized by low levels of Thy-1 and lack of a panel of lineage markers (Thy-1lo Lin- cells) were highly enriched for pluripotent hematopoietic stem cells. In this paper, we present evidence that another bone marrow population, which expressed low levels of Thy-1 and coexpressed B220, a B-lineage-specific form of the leukocyte common antigen, contained early and potent precursors for B lymphocytes upon in vivo transfer to irradiated hosts. These Thy-1lo B220+ cells, comprising 1 to 2% of bone marrow cells, were enriched for large cells in the mitotic cycle; the population lacked significant pluripotent hematopoietic stem cell activity and myeloid-erythroid progenitors. Most strikingly, Thy-1lo B220+ cells represented a highly enriched population of bone marrow cells that could be targets of Abelson murine leukemia virus transformation. We propose that Thy-1lo B220+ bone marrow cells represent the earliest stage of committed lymphocyte progenitors, intermediate in differentiation between Thy-1lo Lin- pluripotent stem cells and, in the B lineage, Thy-1- B220+ pre-B cells.

scholarly journals Demonstration of Thy-1 antigen on pluripotent hemopoietic stem cells in the rat.

1978 ◽  
Vol 148 (5) ◽  
pp. 1351-1366 ◽  
Author(s):  
I Goldschneider ◽  
L K Gordon ◽  
R J Morris
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Cells ◽  
Cell Activity ◽  
Hemopoietic Stem Cell ◽  
Hemopoietic Stem Cells ◽  
Stem Cell Activity ◽  
Series Of Experiments ◽  
Marrow Cells

Three approaches were used to demonstrate the presence of Thy-1 antigen on the surface of pluripotent hemopoietic stem cells in the rat. In the first, stem cells from fetal liver, neonatal spleen, and adult bone marrow were prevented from forming hemopoietic colonies in the spleens of irradiated recipients spleen (colony-forming unit assay) by incubation with antibodies to Thy-1 antigen. Highly specific rabbit heteroantiserum to purified rat brain Thy-1 antigen and mouse alloantisera to Thy-1.1-positive thymocytes were equally effective. This inhibition was neutralized by purified Thy-1 antigen. In a second series of experiments, Thy-1-positive and Thy-1-negative populations of nucleated bone marrow cells were separated by the FACS. All of the hemopoietic stem cell activity was recovered in the Thy-1-positive population. The stem cells were among the most strongly positive for Thy-1 antigen, being in the upper 25th percentile for relative fluorescence intensity. The relationships of Thy-1 antigen to the rat bone marrow lymphocyte antigen (BMLA) was shown in a third series of experiments. Rabbit anti-BMLA serum, which is raised against a null population of lymphocyte-like bone marrow cells, has been shown to have anti-stem cell activity. Here we demonstrate by double immunofluorescence, cocapping, and differential absorption studies that Thy-1 and BMLA are parts of the same molecule.

Sign in / Sign up

Export Citation Format

Share Document